Paradigm Biocapital Advisors LP Nuvalent, Inc. Transaction History
Paradigm Biocapital Advisors LP
- $2.14 Billion
- Q2 2025
A detailed history of Paradigm Biocapital Advisors LP transactions in Nuvalent, Inc. stock. As of the latest transaction made, Paradigm Biocapital Advisors LP holds 5,269,433 shares of NUVL stock, worth $442 Million. This represents 18.77% of its overall portfolio holdings.
Number of Shares
5,269,433
Previous 5,269,433
-0.0%
Holding current value
$442 Million
Previous $374 Million
7.59%
% of portfolio
18.77%
Previous 19.15%
Shares
8 transactions
Others Institutions Holding NUVL
# of Institutions
225Shares Held
59.8MCall Options Held
191KPut Options Held
306K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.51 Billion31.57% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.52MShares$379 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$254 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.8MShares$151 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X01.78MShares$149 Million0.07% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.6B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...